The local medical sector is buzzing with the emergence of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing impressive results in scientific trials for treating obesity. This treatment https://socialmediaentry.com/story7273959/the-new-retatrutide-australia-a-emerging-prospect-for-weight-management